Leerink analyst Geoffrey Porges lowered his price target for Aptinyx to $22 from $35 following the negative result from the phase II study for NYX-2925 in diabetic peripheral neuropathy. The analyst reiterates an Outperform rating on Aptinyx shares as the stock is currently trading around cash levels and further data disclosures from DPN, fibromyalgia, PTSD, and Parkinson's disease cognitive impairment programs later this year could clarify the various opportunities for the company's drug discovery platform.
https://thefly.com/landingPageNews.php?id=2850177
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.